Abstract

The M gene segment of influenza A virus has been shown to be a contributing factor to the high growth phenotype. However, it remains largely unknown why matrix protein 1 (M1), the major structural protein encoded by M gene, exhibits pH-dependent conformational changes during virus replication. Understanding the mechanisms underlying efficient virus replication can help to develop strategies not only to combat influenza infections but also to improve vaccine supplies. M(NLS-88R) and M(NLS-88E) are two M1 mutants differing by only a single amino acid: G88R vs G88E. G88R but not G88E was the compensatory mutation naturally selected by the virus after its nuclear localization signal was disrupted. Our study shows that, compared with M(NLS-88E) M1, M(NLS-88R) M1 dissociated quickly from viral ribonucleoproteins (vRNPs) at higher pH and took less time to dissemble in vitro, despite forming thicker matrix layer and having stronger association with vRNP in assembled virions. Correspondingly, M(NLS-88R) replicated more efficiently and was genetically more stable than M(NLS-88E). Crystallographic analysis indicated that M(NLS-88R) M1, like wild-type M1, is able to switch from a face-to-back-oriented conformation to a face-to-face-oriented conformation when pH drops from neutral to acidic, whereas G88E mutation causes M(NLS-88E) M1 to be trapped in a face-to-face-arranged conformation regardless of environmental pH. Our results suggest that maintaining M1 pH-dependent conformational flexibility is critical for efficient virus replication, and position 88 is a key residue controlling M1 pH-dependent conformational changes. Our findings provide insights into developing M1-based antiviral agents.

Emerging Microbes & Infections (2017) 6, e108; doi:10.1038/emi.2017.96; published online 6 December 2017

Details

Title
Maintaining pH-dependent conformational flexibility of M1 is critical for efficient influenza A virus replication
Author
Meng-Jung, Chiang 1 ; Musayev, Faik N 2 ; Kosikova, Martina 1 ; Lin, Zhengshi 1 ; Gao, Yamei 1 ; Mosier, Philip D 2 ; Althufairi, Bashayer 2 ; Ye, Zhiping 1 ; Zhou, Qibing 3 ; Desai, Umesh R 2 ; Xie, Hang 1 ; Safo, Martin K 2 

 Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD 20993, USA 
 Department of Medicinal Chemistry and Institute for Structural Biology, Drug Discovery and Development, School of Pharmacy Virginia Commonwealth University, Richmond, VA 23298, USA 
 Department of Nanomedicine and Biopharmaceuticals, National Engineering Research Center for Nanomedicine Huazhong University of Science and Technology, Wuhan, Hubei 430074, China 
Pages
1-11
Publication year
2017
Publication date
Jan 2017
Publisher
Taylor & Francis Ltd.
e-ISSN
22221751
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2516721826
Copyright
© The Author(s) 2017. This work is licensed under the Creative Commons Attribution License https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.